Company will produce Trop-2 targeting antibody.
Laureate Pharma entered into a cGMP manufacturing agreement with Arius Research for its Trop-2 signal transduction antibody program.
Laureate will produce Arius’ IgG1 humanized antibody under the agreement. The product targets a novel marker that has been linked to aggressive cancers including pancreatic, colon, breast, and prostate cancer, according to Arius.